- Molecular NameMianserin
- SynonymMianserina [inn-spanish]; Mianserine; Mianserine [inn-french]; Mianserinum [inn-latin]; Mianseryna [polish]
- Weight264.372
- Drugbank_IDDB06148
- ACS_NO24219-97-4
- Show 2D model
- LogP (experiment)4.0
- LogP (predicted, AB/LogP v2.0)3.49
- pkaN/A
- LogD (pH=7, predicted)3.14
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.6
- LogSw (predicted, AB/LogsW2.0)0.14
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds0
- TPSA6.48
- StatusFDA approved
- AdministrationN/A
- PharmacologyA psychoactive drug of the tetracyclic antidepressant (TeCA) chemical class which is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA) and has antidepressant, anxiolytic, hypnotic, antiemetic, orexigenic, and antihistamine effects.
- Absorption_value70.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability22.0
- Protein binding90.0
- Volume of distribution (VD)13 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMianserin is metabolized by three main pathways, namely 8-hydroxylation, demethylation, and 2-oxide formation in human and other mammalian species. In human liver, CYP2D6, 2B6, 3A4 and 1A2 catalyze the 8-hydroxylation, and CYP1A2 and 3A4 are involved exclusively in the N-oxidation, whereas CYP2B6, 2C19, 1A2, 3A4 and 2D6 showed a catalytic activity for the N-demethylation. Beside the major pathways, several minor metabolites was identified: mianserin 2-N-beta-D-glucuronide (only in man), 2-formyl-N-desmethylmianserin and its 8-hydroxylated derivative (in rat).
- Half life6~40 h (mean 16), increased in elderly subjects.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A